Research ExplorerPublicationsLow homoarginine/SDMA ratio is associated with poor short- a...

Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies

Standard

Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies. / Choe, Chi-Un; Lezius, Susanne; Cordts, Kathrin; Gerloff, Christian; Böger, Rainer H; Schwedhelm, Edzard; Grant, Peter J.

In: NEUROL SCI, Vol. 41, No. 1, 01.2020, p. 149-153.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Choe, C-U, Lezius, S, Cordts, K, Gerloff, C, Böger, RH, Schwedhelm, E & Grant, PJ 2020, 'Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies', NEUROL SCI, vol. 41, no. 1, pp. 149-153. https://doi.org/10.1007/s10072-019-04058-0

APA

Choe, C-U., Lezius, S., Cordts, K., Gerloff, C., Böger, R. H., Schwedhelm, E., & Grant, P. J. (2020). Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies. NEUROL SCI, 41(1), 149-153. https://doi.org/10.1007/s10072-019-04058-0

Vancouver

Choe C-U, Lezius S, Cordts K, Gerloff C, Böger RH, Schwedhelm E et al. Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies. NEUROL SCI. 2020 Jan;41(1):149-153. https://doi.org/10.1007/s10072-019-04058-0

Bibtex

@article{73f21138ec714c369388da9729021e10,
title = "Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies",
abstract = "BACKGROUND: Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with cardio- and cerebrovascular events and risk. We aimed to study if low hArg/ADMA and hArg/SDMA ratios are associated with mortality and outcome after stroke.METHODS: In two prospective cohorts of acute stroke patients from Germany and the UK, we analyzed hArg, ADMA, and SDMA to determine hArg/ADMA and hArg/SDMA ratios. The guanidino compound levels were associated with mortality, adverse events, and neurological impairment, i.e., National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS).RESULTS: During 7.4 years, high hArg/ADMA and hArg/SDMA ratios were both associated with a reduction in all-cause mortality in patients with ischemic stroke in a UK stroke cohort (hArg/ADMA: hazard ratio (HR) 0.75 [95% confidence interval (CI) 0.62-0.92]; n = 394; P = 0.006; hArg/SDMA: HR 0.68 [0.54-0.85]; n = 394; P = 0.001). In a German stroke cohort, patients with high hArg/SDMA ratio experienced fewer adverse events compared with those with low hArg/SDMA ratios within 30 days after stroke (HR 0.73 [0.57-0.92]; n = 135; P = 0.009), whereas hArg/ADMA was not predictive. Furthermore, hArg/SDMA ratios inversely correlated with the degree of neurological impairment (NIHSS) (r = - 0.27; P = 0.001; n = 138). Lower hArg/SDMA ratios were also found in dependent (mRS 3-6) compared with independent patients (mRS < 3; P = 0.007; n = 138), whereas hArg/ADMA did not.CONCLUSION: These results from two prospective stroke studies reveal that hArg/SDMA ratio could prove a valuable blood-based biomarker to discriminate patients with poor short- and long-term outcome, increased neurological impairment, and severe disability after stroke.",
author = "Chi-Un Choe and Susanne Lezius and Kathrin Cordts and Christian Gerloff and B{\"o}ger, {Rainer H} and Edzard Schwedhelm and Grant, {Peter J}",
year = "2020",
month = jan,
doi = "10.1007/s10072-019-04058-0",
language = "English",
volume = "41",
pages = "149--153",
number = "1",

}

RIS

TY - JOUR

T1 - Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies

AU - Choe, Chi-Un

AU - Lezius, Susanne

AU - Cordts, Kathrin

AU - Gerloff, Christian

AU - Böger, Rainer H

AU - Schwedhelm, Edzard

AU - Grant, Peter J

PY - 2020/1

Y1 - 2020/1

N2 - BACKGROUND: Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with cardio- and cerebrovascular events and risk. We aimed to study if low hArg/ADMA and hArg/SDMA ratios are associated with mortality and outcome after stroke.METHODS: In two prospective cohorts of acute stroke patients from Germany and the UK, we analyzed hArg, ADMA, and SDMA to determine hArg/ADMA and hArg/SDMA ratios. The guanidino compound levels were associated with mortality, adverse events, and neurological impairment, i.e., National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS).RESULTS: During 7.4 years, high hArg/ADMA and hArg/SDMA ratios were both associated with a reduction in all-cause mortality in patients with ischemic stroke in a UK stroke cohort (hArg/ADMA: hazard ratio (HR) 0.75 [95% confidence interval (CI) 0.62-0.92]; n = 394; P = 0.006; hArg/SDMA: HR 0.68 [0.54-0.85]; n = 394; P = 0.001). In a German stroke cohort, patients with high hArg/SDMA ratio experienced fewer adverse events compared with those with low hArg/SDMA ratios within 30 days after stroke (HR 0.73 [0.57-0.92]; n = 135; P = 0.009), whereas hArg/ADMA was not predictive. Furthermore, hArg/SDMA ratios inversely correlated with the degree of neurological impairment (NIHSS) (r = - 0.27; P = 0.001; n = 138). Lower hArg/SDMA ratios were also found in dependent (mRS 3-6) compared with independent patients (mRS < 3; P = 0.007; n = 138), whereas hArg/ADMA did not.CONCLUSION: These results from two prospective stroke studies reveal that hArg/SDMA ratio could prove a valuable blood-based biomarker to discriminate patients with poor short- and long-term outcome, increased neurological impairment, and severe disability after stroke.

AB - BACKGROUND: Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with cardio- and cerebrovascular events and risk. We aimed to study if low hArg/ADMA and hArg/SDMA ratios are associated with mortality and outcome after stroke.METHODS: In two prospective cohorts of acute stroke patients from Germany and the UK, we analyzed hArg, ADMA, and SDMA to determine hArg/ADMA and hArg/SDMA ratios. The guanidino compound levels were associated with mortality, adverse events, and neurological impairment, i.e., National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS).RESULTS: During 7.4 years, high hArg/ADMA and hArg/SDMA ratios were both associated with a reduction in all-cause mortality in patients with ischemic stroke in a UK stroke cohort (hArg/ADMA: hazard ratio (HR) 0.75 [95% confidence interval (CI) 0.62-0.92]; n = 394; P = 0.006; hArg/SDMA: HR 0.68 [0.54-0.85]; n = 394; P = 0.001). In a German stroke cohort, patients with high hArg/SDMA ratio experienced fewer adverse events compared with those with low hArg/SDMA ratios within 30 days after stroke (HR 0.73 [0.57-0.92]; n = 135; P = 0.009), whereas hArg/ADMA was not predictive. Furthermore, hArg/SDMA ratios inversely correlated with the degree of neurological impairment (NIHSS) (r = - 0.27; P = 0.001; n = 138). Lower hArg/SDMA ratios were also found in dependent (mRS 3-6) compared with independent patients (mRS < 3; P = 0.007; n = 138), whereas hArg/ADMA did not.CONCLUSION: These results from two prospective stroke studies reveal that hArg/SDMA ratio could prove a valuable blood-based biomarker to discriminate patients with poor short- and long-term outcome, increased neurological impairment, and severe disability after stroke.

U2 - 10.1007/s10072-019-04058-0

DO - 10.1007/s10072-019-04058-0

M3 - SCORING: Journal article

C2 - 31482247

VL - 41

SP - 149

EP - 153

IS - 1

ER -